When Vibrio is not cholera: meet Vibrio alginolyticus
DOI:
https://doi.org/10.24197/kzc5nt17Keywords:
Vibrio alginolyticus, external otitis, halophilicAbstract
Vibrio alginolyticus is a Gram-negative, halophilic bacillus capable of tolerating high salt concentrations. It acts as an opportunistic pathogen and commonly causes otitis and skin infections after exposure to seawater or consumption of raw seafood. In individuals with risk factors, it can cause severe infections. Diagnosis is made through culture on TCBS agar, biochemical tests or molecular techniques. Treatment varies according to severity and may include fluoroquinolones, tetracyclines or trimethoprim-sulfamethoxazole. The use of penicillins and first-generation cephalosporins should be avoided due to high resistance.
Downloads
References
1. Mensa Pueyo J, Soriano Viladomiu A. Guía terapéutica antimicrobiana 2025: Mensa Gatell. 35 ed. Barcelona: Antares; 2025.
2. Yu Y, Li H, Wang Y, Zhang Z, Liao M, Rong X, et al. Antibiotic resistance, virulence and genetic characteristics of Vibrio alginolyticus isolates from aquatic environment in costal mariculture areas in China. Mar Pollut Bull. 2022;185:114219.
3. JACOBS SLIFKA KM, NEWTON AE, MAHON BE. Vibrio alginolyticus infections in the USA, 1988–2012. Epidemiol Infect. 2017;145(7):1491-9.
4. Hoefler F, Pouget-Abadie X, Roncato-Saberan M, Lemarié R, Takoudju EM, Raffi F, et al. Clinical and Epidemiologic Characteristics and Therapeutic
5. Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001–2019. Emerg Infect Dis. 2022;28(12).
6. Ma I, Bermejo G. Diagnóstico de las infecciones humanas causadas por especies halófilas del género Vibrio. Control de Calidad SEIMC.
7. Wong KC, Brown AM, Luscombe GM, Wong SJ, Mendis K. Antibiotic use for Vibrio infections: important insights from surveillance data. BMC Infect Dis. 2015;15(1):226.
8. Karatuna O, Matuschek E, Åhman J, Caidi H, Kahlmeter G. Vibrio species: development of EUCAST susceptibility testing methods and MIC and zone diameter distributions on which to determine clinical breakpoints. Journal of Antimicrobial Chemotherapy. 2024;79(2):375-82.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Marta Cano Pérez, Laura Rita Iotti, Belén Francisca Sánchez Borge

This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published at Clínica will have a Creative Commons Attribution 4.0 International License (CC BY 4.0).
The journal allows the authors to retain publishing rights. Authors may reprint their articles in other media without having to request authorization, provided they indicate that the article was originally published in Clínica.
